Ocugen Inc. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, ...
January 12 2021 - 7:52AM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing gene therapies to cure
blindness diseases and developing a vaccine to fight COVID-19,
today announced it has determined to withdraw from stockholder
consideration Item 2 set forth in its Definitive Proxy Statement
filed with the Securities and Exchange Commission on October 30,
2020, with respect to an increase in the number of shares of common
stock authorized for issuance under the Company’s Sixth Amended and
Restated Certificate of Incorporation. As a result, the Company has
determined to cancel the reconvening of its annual meeting of
stockholders, which was previously adjourned solely with respect to
Item 2 to 11:00 a.m. Eastern Time on January 13, 2021. All other
items set forth in the Company’s Definitive Proxy Statement were
submitted to stockholder vote at the Company’s annual meeting of
stockholders on December 23, 2020. The Company plans to re-evaluate
the details of Item 2 in light of the recent potential addition of
COVAXIN™ to its pipeline as well as its compliance with Nasdaq’s
Listing Rule 5550(a)(2).
About Ocugen, Inc.Ocugen, Inc. is a
biopharmaceutical company focused on discovering, developing, and
commercializing gene therapies to cure blindness diseases and
developing a vaccine to fight COVID-19. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with one drug – “one to many,” and our novel biologic
product candidate aims to offer better therapy to patients with
underserved diseases such as wet age-related macular degeneration,
diabetic macular edema, and diabetic retinopathy. For more
information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, which are subject to
risks and uncertainties. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from our current
expectations. These and other risks and uncertainties are more
fully described in our periodic filings with the Securities and
Exchange Commission (the “SEC”), including the risk factors
described in the section entitled “Risk Factors” in the quarterly
and annual reports that we file with the SEC. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. Except as required by law, we assume no
obligation to update forward-looking statements contained in this
press release whether as a result of new information, future events
or otherwise, after the date of this press release.
Corporate Contact:Ocugen, Inc.Sanjay
SubramanianChief Financial OfficerIR@Ocugen.com
Media Contact: LaVoieHealthScience Emmie
Twomblyetwombly@lavoiehealthscience.com+1 857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Sep 2023 to Sep 2024